Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Cash & Equivalents (2016 - 2026)

Insight Molecular Diagnostics' Cash & Equivalents history spans 7 years, with the latest figure at $11.6 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 34.12% to $11.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.6 million, a 34.12% increase, with the full-year FY2025 number at $11.6 million, up 34.12% from a year prior.
  • Cash & Equivalents hit $11.6 million in Q4 2025 for Insight Molecular Diagnostics, down from $18.7 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for IMDX hit a ceiling of $58.9 million in Q1 2021 and a floor of $433000.0 in Q4 2022.
  • Historically, Cash & Equivalents has averaged $19.4 million across 5 years, with a median of $14.5 million in 2023.
  • The widest YoY moves for Cash & Equivalents: up 2078.29% in 2023, down 98.63% in 2023.
  • Tracing IMDX's Cash & Equivalents over 5 years: stood at $904000.0 in 2021, then tumbled by 52.1% to $433000.0 in 2022, then skyrocketed by 2078.29% to $9.4 million in 2023, then decreased by 8.44% to $8.6 million in 2024, then surged by 34.12% to $11.6 million in 2025.
  • Business Quant data shows Cash & Equivalents for IMDX at $11.6 million in Q4 2025, $18.7 million in Q3 2025, and $24.3 million in Q2 2025.